Abstract
Untargeted molecular tests are increasingly available for the diagnosis of infectious diseases. In this national survey, plasma metagenomic next-generation sequencing had widespread use (89.8%), but disparate frequency from a few times ever (18.4%) to > weekly (9.6%). Respondents offered thoughtful insights into stewardship and future research needs.